AstraZeneca Confident For Next Decade Despite Upcoming Patent Cliff
Misses Q4 Sales Consensus Estimate
The UK major believes it can maintain growth trajectory through novel combinations regimens and pipeline diversification despite the anticipated expiration of several blockbuster drug patents over the next decade.
You may also be interested in...
The Japanese drug maker is the second in the space of a month to partner up with a Chinese biotech firm for a HER2-targeting antibody-drug conjugate, as ADCs gain more interest from large pharma firms.
The UK major’s long-acting C5 inhibitor is nearing EU approval for the debilitating rare disease as the company gears up for emerging competition and loss of exclusivity for its older drug Soliris.
The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.